CD8A and B-cell non-Hodgkin lymphoma: Conversely, Ren et al. reported in 2016 that CD8+ T cells alone, but not CD4+ T cells, contributed to the effective anti-mouse CD20 Ab therapy in a syngeneic A20 B-cell lymphoma mouse model.